Welch & Forbes’s Novartis NVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$9.09M Buy
57,984
+358
+0.6% +$53.7K 0.11% 103
2026
Q1
$8.8M Sell
57,626
-3,462
-6% -$531K 0.11% 99
2025
Q4
$8.42M Sell
61,088
-58
-0.1% -$7.59K 0.1% 100
2025
Q3
$7.84M Sell
61,146
-663
-1% -$80.9K 0.09% 109
2025
Q2
$7.48M Buy
61,809
+515
+0.8% +$58K 0.09% 107
2025
Q1
$6.83M Sell
61,294
-1,779
-3% -$189K 0.09% 111
2024
Q4
$6.14M Sell
63,073
-2,503
-4% -$267K 0.08% 117
2024
Q3
$7.54M Sell
65,576
-805
-1% -$91.3K 0.1% 109
2024
Q2
$7.16M Sell
66,381
-2,713
-4% -$272K 0.1% 111
2024
Q1
$6.68M Sell
69,094
-950
-1% -$97.4K 0.09% 114
2023
Q4
$7.07M Sell
70,044
-643
-0.9% -$62.1K 0.11% 109
2023
Q3
$7.2M Sell
70,687
-2,620
-4% -$266K 0.12% 106
2023
Q2
$7.4M Sell
73,307
-1,713
-2% -$171K 0.12% 105
2023
Q1
$6.9M Sell
75,020
-4,771
-6% -$417K 0.12% 109
2022
Q4
$7.24M Sell
79,791
-8,316
-9% -$700K 0.13% 111
2022
Q3
$6.7M Sell
88,107
-1,986
-2% -$165K 0.13% 111
2022
Q2
$7.62M Sell
90,093
-661
-0.7% -$58K 0.14% 109
2022
Q1
$7.96M Sell
90,754
-729
-0.8% -$63.1K 0.13% 116
2021
Q4
$8M Buy
91,483
+2,187
+2% +$182K 0.12% 120
2021
Q3
$7.3M Sell
89,296
-1,590
-2% -$143K 0.12% 119
2021
Q2
$8.29M Buy
90,886
+34
+0% +$3.03K 0.14% 116
2021
Q1
$7.77M Buy
90,852
+1,862
+2% +$167K 0.14% 114
2020
Q4
$8.4M Buy
88,990
+3,846
+5% +$336K 0.16% 106
2020
Q3
$7.4M Buy
85,144
+3,101
+4% +$269K 0.16% 106
2020
Q2
$7.17M Sell
82,043
-254
-0.3% -$21.9K 0.17% 103
2020
Q1
$6.79M Sell
82,297
-250
-0.3% -$22.3K 0.19% 102
2019
Q4
$7.82M Sell
82,547
-1,130
-1% -$101K 0.17% 109
2019
Q3
$7.27M Buy
83,677
+984
+1% +$88.4K 0.17% 111
2019
Q2
$7.55M Sell
82,693
-18,646
-18% -$1.58M 0.18% 107
2019
Q1
$8.73M Sell
101,339
-2,488
-2% -$200K 0.22% 101
2018
Q4
$7.98M Sell
103,827
-53
-0.1% -$4.13K 0.23% 101
2018
Q3
$8.02M Sell
103,880
-19,026
-15% -$1.41M 0.19% 113
2018
Q2
$8.32M Sell
122,906
-1,574
-1% -$109K 0.22% 101
2018
Q1
$9.02M Buy
124,480
+1,372
+1% +$104K 0.23% 101
2017
Q4
$9.26M Buy
123,108
+973
+0.8% +$73.4K 0.25% 97
2017
Q3
$9.4M Buy
122,135
+2,316
+2% +$175K 0.25% 100
2017
Q2
$8.96M Buy
119,819
+3,515
+3% +$249K 0.25% 97
2017
Q1
$7.74M Buy
116,304
+9,387
+9% +$626K 0.22% 107
2016
Q4
$6.98M Buy
106,917
+5,512
+5% +$358K 0.21% 112
2016
Q3
$7.17M Sell
101,405
-1,111
-1% -$81K 0.25% 94
2016
Q2
$7.58M Sell
102,516
-425
-0.4% -$29.4K 0.23% 102
2016
Q1
$6.68M Sell
102,941
-55,306
-35% -$3.76M 0.21% 108
2015
Q4
$12.2M Buy
158,247
+17,023
+12% +$1.35M 0.39% 81
2015
Q3
$11.6M Buy
141,224
+11,651
+9% +$1.04M 0.39% 80
2015
Q2
$11.4M Sell
129,573
-5,772
-4% -$530K 0.36% 81
2015
Q1
$12M Sell
135,345
-5,614
-4% -$498K 0.36% 78
2014
Q4
$11.7M Buy
140,959
+1,753
+1% +$145K 0.34% 79
2014
Q3
$11.7M Buy
139,206
+956
+0.7% +$77.3K 0.36% 79
2014
Q2
$11.2M Buy
138,250
+3,064
+2% +$241K 0.35% 81
2014
Q1
$10.3M Sell
135,186
-2,228
-2% -$162K 0.33% 86
2013
Q4
$9.9M Sell
137,414
-1,512
-1% -$105K 0.31% 86
2013
Q3
$9.55M Sell
138,926
-611
-0.4% -$40.4K 0.32% 87
2013
Q2
$8.84M Buy
+139,537
New +$9.08M 0.32% 86

Other funds holding NVS

Welch & Forbes's NVS Position: Q2 2026 in Review

Welch & Forbes increased its Novartis (NVS) stake by 0.62% in Q2 2026, buying an estimated $53.7K and bringing the position to 57,984 shares worth $9.09M. The position accounts for 0.11% of the portfolio, ranked #103.

Welch & Forbes first reported a position in NVS in Q2 2013 and has held it in 53 quarters since. The position peaked at $12.2M in Q4 2015. 1,611 funds tracked by Wall St. Rank hold NVS as of Q2 2026.

  • Welch & Forbes held 57,984 shares of Novartis worth $9.09M as of Q2 2026.
  • Welch & Forbes bought 358 Novartis shares in Q2 2026, an estimated $53.7K.
  • Novartis made up 0.11% of Welch & Forbes's portfolio in Q2 2026, its #103 holding.
  • Welch & Forbes first reported a position in Novartis in Q2 2013 and has held it in 53 quarters since.
  • Welch & Forbes's Novartis position peaked at $12.2M in Q4 2015.
  • 1,611 funds tracked by Wall St. Rank held Novartis as of Q2 2026.

Based on Welch & Forbes's 13F filing for Q2 2026, filed 30 Jul 2026.